GlobeNewswire
--Cash runway extended late into calendar Q2 2023 --Tumor control achieved following MDNA11 treatment in 3 out of 8 patients enrolled in first 3 dose escalation cohorts of the ABILITY Phase 1/2 Study. -- Pharmacodynamic data show superior dose-dependent increase in stimulation of anti-cancer immune cells when compared to competing IL-2 programs in the clinic -- Management hosting conference call and webcast today at 8:30 AM ET TORONTO and HOUSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Ther